Minireviews
Copyright ©The Author(s) 2019.
World J Crit Care Med. Jun 12, 2019; 8(3): 18-27
Published online Jun 12, 2019. doi: 10.5492/wjccm.v8.i3.18
Table 2 Selected evidence-based research on pharmacological management of delirium in intensive care unit
Ref.AnalysisFindings
Burry et al[41]Cochrane analysisIn non-ICU patients there is a poor evidence about the efficacy of typical, or SGAs, on the duration of delirium, discharge time, or HRQoL
Lonergan et al[42]Cochrane analysisLow dose haloperidol may be effective against POD, although with greater incidence of side effects when compared to the SGAs; Limitation: analysis based on small studies of limited scope
Serafim et al[43]Systematic reviewProphylactic use of haloperidol, may be useful for reducing the prevalence of ICU-D
Herling et al[44]Cochrane analysisNo difference proved between haloperidol and placebo for preventing ICU-D
Tao et al[53]Meta-analysisAdministration of dexamethasone was associated with a reduction in delirium after on-pump cardiac surgery; Limitation: studies at a high risk of bias
Barbateskovic et al[45]Systematic overview of reviews and meta-analysesPharmacological strategies for prevention or management of ICU-D is poor, or sparse
Chen et al[46]Cochrane analysisNo evidence on the preventive and therapeutic role of dexmedetomidine against ICU-D and its outcome
Liu et al[47]Meta-analysisDexmedetomidine may reduce delirium and duration of MV in patients after cardiac surgery when compared with propofol
Pasin et al[48]Meta-analysisDexmedetomidine may reduce delirium also in patients undergoing non-invasive ventilation
Tampi et al[50]Systematic reviewAnticholinesterase inhibitors have no benefit against ICU-D prevention, or treatment
Lonergan et al[24]Cochrane analysisThere is no evidence to support the use of BDZs in the treatment of non-alcohol withdrawal related delirium